Review article

Pharmacological management of perioperative bleeding in cardiac surgery

Hossam Walley, Magdi Yacoub, Hesham Saad*

BACKGROUND

In spite of the growing discoveries in cardiac surgery, perioperative bleeding remains one of the most common causes of morbidity and mortality. Around 50-60% of cardiac surgery patients receive blood transfusions, which are harmful and strongly associated with increased morbidity, mortality, hospital stay, and hospital cost. Patients taken back to the OR for re-exploration and control of bleeding after cardiac surgery, have a four-fold increase in the incidence of sternal infection and mortality. These facts highlight the pressing need of developing further strategies to deal with the problem. Pharmacological management of perioperative bleeding has evolved rapidly over the last few years.

Antifibrinolytics remain a cornerstone of the pharmacologic part of the multimodal blood conservation program. The use of antifibrinolytics (aprotinin, tranexamic acid and ε-aminocaproic acid) in the last two decades is associated with many myths and facts. Choosing which antifibrinolytic agent, to give to which patient, at what dose, remains the ultimate goal for cardiac anesthesiologists.

The recent trial by Paul S. Myles et al. published in the New England Journal of Medicine, represents a welcome addition to the literature. In this trial, for patients undergoing coronary-artery surgery, tranexamic acid was associated with a lower risk of bleeding than a placebo, without a higher risk of death or thromboembolic complications within 30 days of surgery. However, tranexamic acid was associated with a higher risk of postoperative seizures.

We review this particular trial, and the rapidly evolving field of pharmacological management of perioperative bleeding - both in terms of efficacy limitation, and other future discoveries.

FIBRINOLYSIS AND CARDIAC SURGERY

Surgery results in tissue damage and blood loss, and as a result the homeostatic mechanisms are activated. Hemostasis depends on the balance of four processes: anticoagulants and fibrinolysis - which promote bleeding, and procoagulant and antifibrinolysis - which promote coagulation. Imbalance between the four processes results in either excessive bleeding or thrombosis, or both. At the surgical site, the fibrinolysis
activity has been shown to increase 4-8 fold. The degree of fibrinolysis activation depends on the amount of tissue injury and the type of surgery.\textsuperscript{12}

Cardiac surgery, with its combination of massive tissue injury and use of cardiopulmonary bypass, disturbs the harmony of the hemostasis processes. The flow diagram below depicts the activation of the coagulation and fibrinolysis during cardiac surgery [Figure 1].\textsuperscript{11}

Plasminogen is activated by tissue plasminogen activator (t-PA) into plasmin, and plasmin furthers degrades fibrin into fibrin degradation products.\textsuperscript{12}

Studies have shown a five-fold increase in active tissue plasminogen activator level during cardiopulmonary bypass, tissue plasminogen activator progressively increases during cardiopulmonary bypass and remains elevated for up to two hours afterwards.\textsuperscript{13} This increased fibrinolysis consumes fibrinogen, leaving very little available for coagulation.

**ANTIFIBRINOLYTICS AND CARDIAC SURGERY**

As mentioned above, the increased level of tissue plasminogen activator and plasmin during cardiopulmonary bypass has resulted in increased use of antifibrinolytic agents in cardiac surgery [Table 1].\textsuperscript{14}

Aprotinin (a non-specific serine protease inhibitor) inhibits plasmin in a high dose and is the only agent shown to reduce the need for re-exploration.\textsuperscript{15} However, marketing of the drug was suspended in November 2007 after preliminary results of the BART trial, which showed an increasing mortality trend relative to the lysine analogues.

Lysine analogues (ε-aminocaproic acid and tranexamic acid) were frequently used to competitively inhibit the fibrin-binding site on plasminogen, thus reducing the rate of fibrinolysis. Compared to placebo, ε-aminocaproic acid and tranexamic acid reduce the total blood loss and decrease the number of patients requiring blood transfusion.\textsuperscript{16} The Society of Cardiothoracic Surgeons and the Society of Cardiovascular Anesthesiologists
Table 1  Antifibrinolytics agents: drug description, doses, and mechanism of action.\textsuperscript{14}

| Drugs          | Composition                          | Mechanism of action                                                                 | Elimination                  | Pharmacodynamics                      | Suggested dosing in adults                                                                 | Approval                                                                 |
|----------------|--------------------------------------|--------------------------------------------------------------------------------------|------------------------------|----------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Aprotinin      | Protein, isolated from bovine lung tissue | Protease inhibitor; reversibly complexes with the active sites of plasmin, kallikrein, and trypsin; inhibition of fibrinolysis, activated factor XIIa, thrombin-induced platelet activation, and inflammatory response | Predominantly proteolysis, <10\% renal | Initial plasma half-life 150 min and terminal half-life 10 h | 1. “Full dose”: 2 × 10\textsuperscript{6} KIU bolus patient, 2 × 10\textsuperscript{6} KIU bolus CPB, continuous infusion of 5 × 10\textsuperscript{5} KIU. 2. “Half dose”: 1 × 10\textsuperscript{6} KIU bolus patient, 1 × 10\textsuperscript{6} KIU bolus CPB, continuous infusion of 2.5 × 10\textsuperscript{5} KIU | Suspended since 2008; suspension lifted in Canada in 2011 and Europe in 2012; In the United States still suspended |
| Tranexamic acid| Synthetic lysine analog               | Antifibrinolytic; competitive inhibition of the activation of plasminogen to plasmin | Renal                        | Plasma half-life 3 h                    | 1. “High dose”: 30 mg/kg bolus patient, 2 mg/kg CPB, and continuous infusion of 16 mg/kg; 2. “Low dose”: 10 mg/kg bolus patient, 1-2 mg CPB, and continuous infusion of 1 mg/kg | United States, Canada, Europe                                          |
| ε-Aminocaproic acid | Synthetic lysine analog               | Antifibrinolytic; competitive inhibition of the activation of plasminogen to plasmin | Renal                        | Plasma half-life 2 h                    | 100 mg/kg bolus patient, 5 mg/kg CPB, and continuous infusion of 30 mg/kg                | United States, Canada                                                  |

Notes. CPB, cardiopulmonary bypass; KIU, Kallikrein International Unit.
updated the 2011 guidelines on blood conservation, which recommend the use of lysine analogues (class 1A evidence).\textsuperscript{9}

**CRACKING THE APROTININ DILEMMA**

Aprotinin, in high doses, is the only agent shown to reduce re-exploration after cardiac surgery.\textsuperscript{15} In 2006, the question of aprotinin use in cardiac surgery was raised after the publication of two observational studies. The first, conducted by Mangano et al.,\textsuperscript{17} showed that aprotinin is associated with increased risk of cardiovascular events, cerebrovascular events and renal dysfunction. The second study was conducted by Karkouti et al.,\textsuperscript{18} and showed an increased risk of renal toxicity with the use of aprotinin [Table 2].\textsuperscript{14}

However, these two studies were observational, non-randomized, and both compared aprotinin to products that were not FDA-approved at that time.

In 2007, Bayer released the results of a self-commissioned observational study showing an increase in kidney damage, congestive heart failure, stroke, and mortality.\textsuperscript{19} At the same time, the BART study (the blood conservation using antifibrinolytics in a randomized trial) showed increased mortality with aprotinin compared to lysine analogues.\textsuperscript{20} In November 2007, Bayer temporarily suspended marketing of the drug at the request of Health Canada. By May 2008, Bayer had removed the remaining stocks and withdrawn aprotinin from the worldwide market.

Proponents of aprotinin refused to let its withdrawal from the market be the end of the story. They felt there much needless suffering by patients by not being able to use aprotinin. Hence, questions were raised about the research methods and data analysis of the BART trial.\textsuperscript{21–23}

In December 2008, Health Canada set up an expert advisory panel to discuss the benefit/risk issues of aprotinin and the panelists were asked very specific questions.\textsuperscript{24}

The panel found some of the hidden mystery behind the BART trial

1. The primary outcome in the BART trial was risk of massive bleeding, not mortality.
2. The trial was not sufficiently powered to detect the difference in mortality.

**Table 2  Summary of studies that assessed the safety of Aprotinin.\textsuperscript{14}**

| Authors            | Year | Design                        | Aprotinin (n) | Control (n) | Death | Kidney dysfunction | Kidney failure |
|--------------------|------|-------------------------------|---------------|-------------|-------|-------------------|---------------|
| Karkouti et al.\textsuperscript{6} | 2006 | Case–control propensity       | 449           | TXA: 449    | NS    | ↑                 | NS            |
| Mangano et al.\textsuperscript{3}  | 2006 | Case–control propensity       | 1,295         | TXA: 822; EACA: 823 | ↑     | ↑                 | ↑             |
| Schneeweiss et al.\textsuperscript{4} | 2008 | Observational propensity      | 33,517        | EACA: 44,682 | ↑     | NS                | NS            |
| Shaw et al.\textsuperscript{5}      | 2008 | Retrospective                 | 1,343         | EACA: 6,776 | ↑     | ↑                 | ↑             |
| Fergusson et al.\textsuperscript{8} | 2008 | RCT                           | 781           | TXA: 770; EACA: 780 | ↑     | NS                | NS            |
| Karkouti et al.\textsuperscript{6}  | 2010 | Retrospective propensity      | 1,017         | TXA: 1,544 | NS    | NS                | ↑             |
| Walkden et al.\textsuperscript{7}   | 2013 | Case–control propensity       | 1,754         | TXA: 1,754 | NS    | ↓                 | ↓             |

**Notes.**

↑ is increased with aprotinin; ↓ is increased in control.

\*\textsuperscript{P} = 0.05 for aprotinin vs. TXA and \textsuperscript{P} = 0.06 for EACA.

\textsuperscript{1}Aprotinin significantly increased the incidence of acute kidney injury in low-risk and intermediate-risk patients (\textsuperscript{P} = 0.006), and no difference observed in high-risk patients (\textsuperscript{P} = 0.8).

\textsuperscript{2}Difference observed in the whole population, but no difference when considering only high-risk patients.

EACA, ε-Aminocaproic acid; NS, not statistically significant; RCT, randomized controlled trial; TXA, tranexamic acid.
3- Even though the BART trial was proposed for high-risk patients, the panel found that the patients belonged to the moderate risk group. High-risk patients were either not enrolled or excluded from the trial.

4- The data of 137 patients excluded after randomization was requested and provided by the researchers. The aprotinin group in this subgroup showed lower mortality and no satisfactory explanation was provided.

5- Combining data from both the included and the excluded patients showed that mortality in the aprotinin group was not statistically significantly higher and could have occurred by chance.

The panel concluded that risk/benefit ratio for aprotinin was still favorable as the trials for its initial approval were still relevant. However, further studies were needed to define the risk/benefit of aprotinin. The panel did not find any advantage of aprotinin in low-risk patients, with an expected blood transfusion of one to three units. In these situations, blood transfusion would be safer than aprotinin.24

In September 2011, Health Canada sent a letter to all health professionals informing them of the lifting of the temporary suspension of aprotinin in Canada. Aprotinin has been authorized to be used only for isolated CABG surgery in Canada, and only after careful consideration of the potential risks and benefits.24

ARE TRANEXAMIC ACID AND ε-AMINOCAPROIC ACID ADEQUATE SUBSTITUTE FOR APROTININ?

Analogues of the amino acid lysine

Tranexamic acid and ε-aminocaproic acid are synthetic antifibrinolytic amino acids that competitively block the lysine-binding site of both plasminogen and plasmin, therefore inhibiting each enzyme action. Plasmin can no longer bind to fibrin and can no longer degrade fibrin, and thus bleeding is reduced.14

Tranexamic acid and ε-aminocaproic acid have a small molecular weight and half life of about two to three hours. On a molar basis, TA is at least seven times more potent than EACA.14

TA is more effective relatively to EACA in reducing the need for blood transfusion in cardiac surgery. TA saved an average of 300 ml of blood per patient during cardiac surgery, with relative risk reduction of 32% in receiving blood transfusion. EACA saved an average of about 200 ml of blood during cardiac surgery, with 30% relative risk reduction in blood transfusion.16

As mentioned by Beverly Hunt in 2014 “There has been an explosion of interest in the ability of tranexamic acid to reduce morbidity and mortality in surgical and traumatic bleeding. Tranexamic acid has been shown to reduce mortality due to traumatic bleeding by a third, without apparent safety issues. It is now clearly established that intravenous tranexamic acid reduces blood loss in patients with surgical bleeding and the need for transfusion”.25

The Myles et al. trial,10 with 2-by-2 factorial design, randomly assigned patients who were scheduled to undergo coronary-artery surgery and were at risk for perioperative complications, to receive aspirin or placebo and tranexamic acid or placebo. The primary outcome was a composite of death and thrombotic complications (non-fatal myocardial infarction, stroke, pulmonary embolism, renal failure, or bowel infarction) within 30 days of surgery.

No evidence was found that the use of tranexamic acid resulted in a higher risk of death or thrombotic complications than with placebo. They also found that the
tranexamic acid group had a lower risk of blood loss, blood transfusion, and reoperation, but a higher risk of postoperative seizures, than the placebo group.\textsuperscript{10}

The most interesting question based on previous data is, “Are the analogues of the amino acid lysine adequate substitutes for aprotinin?”\textsuperscript{26}

Sander et al.,\textsuperscript{26} compared high dose TA to aprotinin and found that the TA group was associated with an increased rate of re-exploration, chest tube drainage and postoperative seizures, while the aprotinin group was associated with increased rate of late ischemic stroke and neurological disorders.

Postoperative seizures reported after the use of TA was an alarming sign about the use of TA in cardiac surgery. Furtmüller et al.,\textsuperscript{27} explain that the seizures associated with the use of lysine analogues could be due to γ-aminobutyric acid (A) \[GABA\] receptor antagonism with possible involvement of other receptors. Figure 2 showing the similarities in the chemical structures of tranexamic acid, GABA, and glycine.\textsuperscript{14} Iplikçigil and Berkman suspect that cerebral ischemia caused by either vasospasm or thrombosis may be the cause of TA-induced seizures.\textsuperscript{28} Table 3 summarizes studies assessing the seizures and mortality associated with tranexamic acid.

**WHAT IS THE PROPER DOSE OF TRANEXAMIC ACID IN CARDIAC SURGERY?**

Despite a wide variety of dosing regimens being examined,\textsuperscript{11} this controversial question has never been properly answered.

Armelin et al.,\textsuperscript{29} compared the low and high doses of TA and found no difference in blood loss or transfusion requirements. The plasma concentration of TA that is required to inhibit fibrinolysis \textit{in vitro} is 10 µg/ml.\textsuperscript{30} The dose of TA that is needed to maintain plasma concentration of above 20 µg/ml has been calculated as: Loading dose: 5.4 mg/kg, CPB prime dose: 50 mg for 2.5 L circuit, and rate of infusion: 5 mg/kg/h, with adjustment to the loading and prime dose in renal insufficiency.\textsuperscript{31}

Dowd et al.,\textsuperscript{32} studied the pharmacokinetics of TA during cardiopulmonary bypass and they found that a TA concentration of 127 µmol is sufficient to provide \textgreater\textbf{90}\% inhibition of the tissue activators of fibrinolysis and is the minimum therapeutic plasma concentration.

In the CRASH-2 trial,\textsuperscript{33} even a very low dose (bolus of 1 g followed by infusion of 1 g over eight hours) was effective in reducing the all-cause mortality. However, another randomized trial by Bokesch et al.,\textsuperscript{34} reported greater efficacy, fewer seizures, and lower mortality, with the same higher dosage as used in the BART trial.

In the Myles et al. trial,\textsuperscript{10} they used a dose of 100 mg/kg at the beginning of the trial, but later reduced this dose because of the growing number of reports of seizures associated with tranexamic acid that were believed to be dose-related. The smaller dose (50 mg/kg) did not reduce the risk of seizures.
| TXA Dose | Patients (n) | Seizures | Mortality | Notes |
|----------|--------------|----------|-----------|-------|
| Total    | Control (%)  | TXA (%)  | P Value   |       |
|          | 6.9          | 8.6      | 0.34      |       |
| Sander et al. [26] | 50 mg/kg bolus; 50 mg/kg CPB | 0.9 | 2.7 | 0.05 |
|          | Aprot = 557  |          |          |       |
|          | Total = 893; TXA = 336; Aprot = 557  | 1.9 | 6.7 | 0.04 |
| Koster et al. [27] | 1 g bolus/0.5 g CPB/infusion 0.2 g/h | 1.2 | 1.8 | 0.32 |
|          | Total: N = 4,883, TXA = 1,029, Aprot = 3,854  | 1.3 | 3.0 | 0.04 |
|          | Open: Heart = 2,779, TXA = 636, Aprot = 2,143  |       |       |       |
| Makhija et al. [28] | 10 mg/kg bolus/infusion 1 mg kg⁻¹ h⁻¹ | 3.3 | 10 | 0.19 |
|          | TXA = 31, EACA = 30  |       |       |       |
| Martin et al. [29] | 2 g bolus/2 g CPB/infusion 0.5 g/h | 3.3 | 7.6 | 0.019 |
|          | TXA = 275, EACA = 329  |       |       |       |
| Martin et al. [30] | 50 mg/kg boluses before and after CPB; 100 mg/100 ml CPB prime | 0.8 | 3.5 | 0.203 |
|          | TXA = 114, EACA = 120  |       |       |       |

Notes.
Aprot, aprotinin; CPB, cardiopulmonary bypass; EACA, ε-aminocaproic acid; TXA, tranexamic acid.
OUTLOOK ON GENOMICS AND FUTURE

Despite an improved understanding of the hemostasis process during cardiopulmonary bypass, it is very difficult to predict which patient is at a higher risk for bleeding or thrombosis. Defects in coagulation proteins, like plasminogen activator inhibitor-1, factor VII, fibrinogen, and t-PA, have a strong heritability profile.35 Welsby et al.,36 identified seven genetic polymorphisms associated with bleeding after cardiac surgery and concluded that although genetic factors appear primarily independent, combining genetic and clinical factors doubles the ability to predict bleeding after cardiac surgery. Accounting for genotype may be necessary when stratifying risk of bleeding after cardiac surgery.

WHAT WE HAVE LEARNED?

Perioperative bleeding in cardiac surgery is not just a surgical problem, but a combination of surgical, medical, and hereditary problems. Facing perioperative bleeding in cardiac surgery is not a death sentence, but an alert to the surgeon, anesthesiologist, and intensivist to corroborate for its management. The prediction of the high-risk patient along with the use of antifibrinolytics may catch the problem but with cost. Choosing which antifibrinolytics to which patient at what dose should be applied for every patient individually according to the risk/benefit ratio regardless the cost-effectiveness.

REFERENCES

[1] Karkouti K, Wijeysundera DN, Yau TM, Beattie WS, Abdelnaem E, McCluskey SA, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion. 2004;44:1453–62.
[2] Mehta RH, Sheng S, O’Brien SM, Grover FL, Gammie JS, Ferguson TB, et al. Reoperation for bleeding in patients undergoing coronary artery bypass surgery: Incidence, risk factors, time trends and outcomes. Circ Cardiovasc Qual Outcomes. 2009;2:583–90.
[3] Daly DJ, Myles PS, Smith JA, Knight JL, Clavisi O, Bain DL, et al. Anticoagulation, bleeding and blood transfusion practices in Australasian cardiac surgical practice. Anaesth Intensive Care. 2007;35:760–8.
[4] Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007;116:2544–52.
[5] Engoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg. 2002;74:1180–6.
[6] Rogers MA, Blumberg N, Saint SK, Kim C, Nallamothu BK, Langa KM. Allogeneic blood transfusions explain increased mortality in women after coronary artery bypass graft surgery. Am Heart J. 2006;152:1028–34.
[7] Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229–39.
[8] Bridges CR. Valid comparisons of antifibrinolytic agents used in cardiac surgery. Circulation. 2007;115:2790–2.
[9] Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, et al. 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines. Ann Thorac Surg. 2011;91:944–82.
[10] Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et al. Tranexamic acid in patients undergoing coronary-artery surgery. New England Journal of Medicine. 2016; NEJMoa1606424.
[11] Dhir A. Antifibrinolytics in cardiac surgery. Annals of Cardiac Anaesthesia. 2013;16(2):117–25.
[12] Davies AJ, Strachan CJ, Hurlow RA, Stuart J. Fibrinolytic activity of tissue surfaces during surgery. Journal of Clinical Pathology. 1979;32(8):822–825.
[13] Chandler WL, Velan T. Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass. Thromb Res. 2003;112:185–92.
[14] Koster A, Farooni D, Levy JH. Antifibrinolytic therapy for cardiac surgery: An update. Anesthesiology. 2015;123(4):214–221.
[15] Brown JR, Birkmeyer NJ, O’Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation. 2007;115:2801–13.
[16] Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, Ferguson DA, Ker K, et al. Anti-fibrinolytic use for minimizing perioperative Allogenic blood transfusion (Review). The Cochrane Library 2011, Issue 3.
[17] Mangano DT, Tudor IC, Dietzel C, Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. *N Engl J Med*. 2006;354:353–65.

[18] Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. *Transfusion*. 2006;46:327–38.

[19] Report on Trasylol for Bayer Corporation and Bayer AG by Zuckerman Spaeder LLP, August 2007. Available from: http://www.pharma.bayer.com/html/pdf/BAYER_REPORT_FINAL_8-007PDF [Last accessed on 2008 Jan 08].

[20] Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogs in High-Risk cardiac surgery. *N Engl J Med*. 2008;358:2319–31.

[21] Sundt TM. The demise of aprotinin: Our share of the blame. *J Thorax Cardiovasc Surg*. 2008;135:729–31.

[22] Royston D, van Haften N, de Vooght P. Aprotinin: Friend or foe? A review of recent medical literature. *Eur J Anaesthesiol*. 2007;24:6–14.

[23] Tempe DK, Hasija S. Are tranexamic acid and ε-aminocaproic acid adequate substitutes for aprotinin? *Ann Card Anaesth*. 2012;15:4–5.

[24] Health Canada decision on Trasylol (aprotinin). Available from: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2011/2011_124-eng.php. [Last accessed on 21 Mar 2013].

[25] Hunt BJ. The current place of tranexamic acid in the management of bleeding. *Anaesthesia*. 2015;70:e18–53.

[26] Sander M, Spies CD, Martiny V, Rosenthal C, Wenneke KD, von Heymann C. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: A retrospective analysis. *Crit Care*. 2010;14:R248.

[27] Furtmüller R, Schlag MG, Berger M, Hopf R, Huck S, Sieghart W, et al. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid (A) receptor antagonistic effect. *J Pharmacol Exp Ther*. 2002;301:168–73.

[28] Iplikcioglu AC, Berkman MZ. The effect of short-term antifibrinolytic therapy on experimental vasospasm. *Surg Neurol*. 2003;59:10–6.

[29] Armellin G, Vinciguerra A, Bonato R, Pittarello D, Giron GP. Tranexamic acid in primary CABG surgery: High vs low dose. *Minerva Anestesiol*. 2004;70:97–107.

[30] Andersson L, Nilsson IM, Colleen S, Granstrand B, Melander B. Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. *Ann N Y Acad SCI*. 1968;146:642–58.

[31] Fiechtner BK, Nuttall GA, Johnson ME, Dong Y, Sujirattanawimol N, Oliver Jr WC, et al. Plasma tranexamic acid concentrations during cardiopulmonary bypass. *Anesth Analg*. 2001;92:1131–6.

[32] Dowd NP, Karski JM, Cheng DC, Carroll JA, Lin Y, James RL, et al. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. *Anesthesiology*. 2002;97:390–9.

[33] The CRASH-2 Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial. *Lancet*. 2010;376:23–32.

[34] Bokesch PM, Szabo G, Wojdyga R, Grocott HP, Smith PK, Mazer CD, et al. A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss in high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial). *J Thorax Cardiovasc Surg*. 2012;143:1022–9.

[35] Perry TE, Muehlschlegel JD, Body SC. Genomics: risk and outcomes in cardiac surgery. *Anesthesiol Clin*. 2008;26:399–417.

[36] Welsby IJ, Podgoreanu MV, Mathew JP, Smith PK. Genetic factors contribute to bleeding after cardiac surgery. 2005;1206–1212.